Aspira Pathlab & Diagnostics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 93.87 million compared to INR 110.49 million a year ago. Revenue was INR 97.32 million compared to INR 112.97 million a year ago. Net loss was INR 21.69 million compared to net income of INR 1.71 million a year ago. Basic loss per share from continuing operations was INR 2.11 compared to basic earnings per share from continuing operations of INR 0.17 a year ago. Diluted loss per share from continuing operations was INR 2.11 compared to diluted earnings per share from continuing operations of INR 0.17 a year ago.